There are many factors that come together to make human beings a special species, but if we are being honest, nothing is really more valuable than our tendency to grow on a consistent basis. You see, when an individual is able to get under all possible situations, it really makes them eligible for some significant milestones along their journey. The same dynamic is notably evident in whatever we have achieved so far, with one huge piece of representation also coming from an idea called technology. Technology’s emergence was, in fact, one of the most pivotal moments in our history, considering the way it just introduced a set of offerings that we could have never even conceived otherwise. In case the stated feature wasn’t enough on its own, this unprecedented nature will end up spreading across the entire spectrum, including our highly-important medical sector. The result here is going to be a famous medtech concept that will revolutionize how we looked at the healthcare space. Nevertheless, even after achieving such a monumental feat, technology will continue to improve the world’s medical prospects in one capacity or the other. If anything, this pattern should only grow stronger on the back of a recent development.
Minnetronix Medical, a contract developer based in St. Paul, has successfully developed an expandable deep brain access port called MindsEye, which is designed to remove lesions in the brain that are caused by conditions like cancer, stroke, and more. Now, while we already have specified procedures for the stated purpose, almost all of them have proven to be hugely invasive, and consequentially, dangerous. MindsEye, on the other hand, is equipped to carry out the task without triggering much of a commotion. Cleared by the FDA back in August 2020, the device is actually the first ever expandable brain access port on the market. Interestingly enough, it’s also the first product Minnetronix has commercialized during its 26 years of journey so far. Up until now, the company had kept itself to developing products for other organizations. Talk about what sub-disciplines Minnetronix captured in those developments, it has tapped into some critical categories such as optical systems, radio frequency energy, stimulation and active wearables, and fluid and gas management. Minnetronix’s excellence around here becomes more apparent once you run through the company’s esteemed clientele, which includes Medtronic, Abbott, United Therapeutics, Boston Scientific, Minerva Surgical, and plenty more industry leaders.
“Its benefits to neurosurgeons — such as expandability, easier insertion and removal, and transparency that minimizes glare and allows surgeons to see surrounding tissue — are truly unique,” said Dr. Johnny Delashaw, neurosurgeon at Tulane University. “The MindsEye expandable port has raised the bar for standard of care in neurosurgery and will improve patient outcomes.”
Beyond MindsEye, Minnetronix is also working on a device called Neurapheresis. Going by the available details, it is basically “a very novel system that is essentially like dialysis for your cerebral spinal fluid.” The company has already completed two prospective, multicenter U.S. clinical trials with the product and it is currently looking to recruit a partner for handling the distribution operation.
